Last quarter (Q4 2023), Kala Pharmaceuticals's total revenue was $―, a decrease of ― from the same quarter last year. In Q4, Kala Pharmaceuticals's net income was $-8.63M. See Kala Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	-	-	$ 3.89M	$ 11.24M	$ 6.36M	$ 6.07M
Cost of Revenue	-	-	-	-	$ 3.17M	$ 2.01M
Gross Profit	-	-	$ 3.89M	-	$ 3.19M	$ 4.07M
Operating Expense	$ 39.66M	$ 39.66M	$ 85.60M	$ -141.49M	$ 99.42M	$ 92.29M
Operating Income	$ -38.95M	$ -39.66M	$ -81.71M	$ -141.49M	$ -96.23M	$ -88.22M
Net Non Operating Interest Income Expense	$ -3.10M	$ -3.10M	$ -6.60M	$ -8.28M	$ -8.10M	$ -6.12M
Other Income Expense	$ -567.00K	$ -567.00K	$ -43.49M	$ -7.15M	-	-
Pretax Income	$ -44.41M	$ -41.18M	$ -39.00M	$ -142.61M	$ -104.33M	$ -94.35M
Tax Provision	-	-	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	$ -4.00K	-	-
Net Income Common Stockholders	$ -42.20M	$ -42.20M	$ -44.82M	$ -142.61M	$ -104.33M	$ -94.35M
Basic EPS	$ -17.93	$ -17.35	$ -29.48	$ -2.19	$ -1.99	$ -2.76
Diluted EPS	$ -17.93	$ -17.35	$ -29.48	$ -2.19	$ -1.99	$ -2.76
Basic Average Shares	$ 9.73M	$ 2.43M	$ 1.52M	$ 65.20M	$ 52.38M	$ 34.21M
Diluted Average Shares	$ 9.73M	$ 2.43M	$ 1.52M	$ 65.20M	$ 52.38M	$ 34.21M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 39.66M	$ 39.66M	$ 85.60M	$ -141.49M	$ 102.59M	$ 94.30M
Net Income From Continuing And Discontinued Operation	$ -42.20M	$ -42.20M	$ -44.82M	$ -142.61M	$ -104.33M	$ -94.35M
Normalized Income	$ -16.01M	$ -32.53M	$ -77.81M	-	$ -104.33M	$ -94.35M
Interest Expense	-	-	-	-	$ 8.59M	$ 8.48M
EBIT	$ -38.60M	$ -35.37M	$ -31.74M	$ -134.23M	$ -95.74M	$ -85.87M
EBITDA	$ -37.04M	$ -33.81M	$ -29.77M	$ -131.71M	$ -94.83M	$ -85.02M

Currency in USD

Kala Pharmaceuticals Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing